Your weekly free stock picks from BeefySignals! 🥩

🥩 BeefySignals Tech Value & Biotech Breakout!
🔍 Recommended date: March 13, 2026

🥩 Stock: CDW Corporation
💹 Ticker: CDW
💼 Sector: Technology
🎯 Estimated return: 2.13% to 5.54%
📅 Date of maximum return: July 9, 2026 (118 days left)

What's the setup:

Technical Signal:
Our system flagged CDW after the stock closed below its lower Bollinger Band — a signal that typically indicates short-term oversold conditions where selling pressure has pushed the price beyond its normal statistical range. Historically, this type of extreme reading in a fundamentally strong business often precedes a mean-reversion bounce back toward fair value.

Recent Performance:
CDW reported strong Q4 2025 results on February 4, 2026: net sales of $5.51 billion (up 6.3% year-over-year), non-GAAP EPS of $2.57 beating estimates of $2.44, and gross profit up 8.6% to $1.254 billion. The stock rose 6.36% immediately following the announcement.

Why It Matters:

• 2026 growth target: Mid single-digit EPS growth, aiming to outperform the US IT market by 200 to 300 basis points​
• AI momentum building: Cloud and SaaS revenues now represent 36% of gross profit, growing fast​
• Full-year 2025 revenue: $22.42 billion, up 6.8% year-over-year​
• Strong cash returns: Returned 90% of adjusted free cash flow to shareholders in 2025, exceeding its 50 to 75% target​
• Dividend growing: Quarterly dividend of $0.630 per share, committed to annual increases​
• Buyback capacity: Over $680 million remaining under current repurchase authorization​

The Opportunity:
A close below the lower Bollinger Band in a company that just beat earnings, raised shareholder returns, and is riding the AI infrastructure wave creates a textbook oversold entry. The pullback looks technical, not fundamental.

🥩 Stock: Bio-Techne Corporation
💹 Ticker: TECH
💼 Sector: Healthcare
🎯 Estimated return: 2.13% to 5.54%
📅 Date of maximum return: July 9, 2026 (118 days left)

What's the setup:

Technical Signal:
Two powerful signals triggered simultaneously: trading volume exceeded 3 standard deviations above the 20-day average (indicating an unusually large surge in buying or selling activity), combined with the close falling below the lower Bollinger Band. This combination often signals capitulation — where a rush of sellers exhausts itself — and can mark a significant short-term low in a quality business.

Recent Performance:
Bio-Techne reported Q2 fiscal 2026 results on February 4, 2026, beating both EPS and revenue estimates. Adjusted EPS of $0.46 beat the $0.43 forecast (up 10% year-over-year), and revenue of $295.9 million exceeded the $290.42 million estimate. The stock jumped 5.93% in pre-market trading following the announcement.

Why It Matters:

• EPS growth: Adjusted EPS up 10% year-over-year despite flat revenue — driven by margin expansion​
• Operating margin improvement: Adjusted operating margin of 31.1%, up 100 basis points year-over-year​
• Strong gross margins: 68.5% adjusted gross margin — best-in-class for life science tools​
• Geographic expansion: Strong growth in China and APAC regions providing new revenue tailwinds​
• Q4 outlook: Management guided mid single-digit growth for Q4 fiscal 2026​
• Debt reduction: Bank debt reduced by $40 million sequentially to $260 million​
• Recovery catalyst: Biotech funding normalization expected by Q1 FY2027, unlocking a major growth driver​

The Opportunity:
An extreme volume spike combined with a close below the lower Bollinger Band in a high-margin life science tools company that just beat earnings points to a capitulation event. When quality businesses see this type of signal, the subsequent recovery can be swift and meaningful.

🐂 Remember Beefies - Stay Beefy. Stay Bullish! 🐂

Regards,

The BeefySignals Team

Follow us on